BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang T, Qiao M, Zhao C, Li X, Gao G, Su C, Ren S, Zhou C. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis. Cancer Immunol Immunother 2018;67:713-27. [PMID: 29423649 DOI: 10.1007/s00262-018-2126-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Battaglia A, Buzzonetti A, Fossati M, Scambia G, Fattorossi A, Madiyalakan MR, Mahnke YD, Nicodemus C. Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. Cancer Immunol Immunother 2020;69:383-97. [PMID: 31897661 DOI: 10.1007/s00262-019-02456-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
2 Li M, Kaili D, Shi L. Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 19-37 [DOI: 10.4251/wjgo.v14.i1.19] [Reference Citation Analysis]
3 Chen D, Mao Y, Zheng Y, Wen J, Song P, Xue Y, Wang W, Sang Y, Chen Y, Dai C. Extracapsular lymph node involvement is a robust survival predictor in esophageal cancer patients: A pooled analysis. Eur J Surg Oncol 2021;47:1875-82. [PMID: 33795171 DOI: 10.1016/j.ejso.2021.03.247] [Reference Citation Analysis]
4 Yang Q, Deng H, Xia H, Xu M, Pan G, Mao J, Tao S, Yamanaka K, An Y. High NF-E2-related factor 2 expression predicts poor prognosis in patients with lung cancer: a meta-analysis of cohort studies. Free Radical Research 2020;54:790-8. [DOI: 10.1080/10715762.2019.1642472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Cao D, Xu H, Xu X, Guo T, Ge W. A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies. Oncoimmunology 2018;7:e1507262. [PMID: 30377569 DOI: 10.1080/2162402X.2018.1507262] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
6 Akce M, Liu Y, Zakka K, Martini DJ, Draper A, Alese OB, Shaib WL, Wu C, Wedd JP, Sellers MT, Bilen MA, El-Rayes BF. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. Am J Clin Oncol 2021;44:74-81. [PMID: 33350681 DOI: 10.1097/COC.0000000000000787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Kang BW, Chau I. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. ESMO Open 2020;5:e000791. [PMID: 32817133 DOI: 10.1136/esmoopen-2020-000791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Peng X, Zeng W, Tang B, He A, Zhang M, Luo R. Utility of Pretreatment Blood Platelet-To-Lymphocyte Ratio in Prediction of Clinical Outcomes and Chemosensitivity in Patients with Advanced Gastric Cancer: A Meta-Analysis. Med Sci Monit 2022;28:e933449. [PMID: 35095093 DOI: 10.12659/MSM.933449] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med 2020;18:360. [PMID: 33213430 DOI: 10.1186/s12916-020-01817-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
10 Mao Y, Chen D, Duan S, Zhao Y, Wu C, Zhu F, Chen C, Chen Y. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis. Cancer Cell Int 2018;18:201. [PMID: 30534002 DOI: 10.1186/s12935-018-0698-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
11 Meireson A, Tavernier SJ, Van Gassen S, Sundahl N, Demeyer A, Spaas M, Kruse V, Ferdinande L, Van Dorpe J, Hennart B, Allorge D, Haerynck F, Decaestecker K, Rottey S, Saeys Y, Ost P, Brochez L. Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. Cancers (Basel) 2021;13:2630. [PMID: 34071888 DOI: 10.3390/cancers13112630] [Reference Citation Analysis]
12 Wang X, Chen D, Wen J, Mao Y, Zhu X, Fan M, Chen Y. Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: a systematic review and meta-analysis. Ann Transl Med 2021;9:1430. [PMID: 34733982 DOI: 10.21037/atm-21-4001] [Reference Citation Analysis]
13 Katayama Y, Shimamoto T, Yamada T, Takeda T, Yamada T, Shiotsu S, Chihara Y, Hiranuma O, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. J Clin Med 2019;9:E102. [PMID: 31906082 DOI: 10.3390/jcm9010102] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
14 Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, Ren S, Chen X, Zhou C. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung Cancer 2019;130:76-83. [PMID: 30885355 DOI: 10.1016/j.lungcan.2019.02.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
15 Ozdemir Y, Topkan E, Mertsoylu H, Selek U. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy. Cancer Manag Res 2020;12:1959-67. [PMID: 32214853 DOI: 10.2147/CMAR.S248034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Honrubia-Peris B, Garde-Noguera J, García-Sánchez J, Piera-Molons N, Llombart-Cussac A, Fernández-Murga ML. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers (Basel) 2021;13:4280. [PMID: 34503087 DOI: 10.3390/cancers13174280] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non–Small-Cell Lung Cancer: An External Validation. Clinical Lung Cancer 2020;21:e337-48. [DOI: 10.1016/j.cllc.2020.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wang J, Zhang F, Jiang F, Hu L, Chen J, Wang Y. Distribution and reference interval establishment of neutral-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in Chinese healthy adults. J Clin Lab Anal 2021;35:e23935. [PMID: 34390017 DOI: 10.1002/jcla.23935] [Reference Citation Analysis]
19 Wang Z, Zhan P, Lv Y, Shen K, Wei Y, Liu H, Song Y. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. Transl Lung Cancer Res 2019;8:214-26. [PMID: 31367535 DOI: 10.21037/tlcr.2019.06.10] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
20 Bellesoeur A, Torossian N, Amigorena S, Romano E. Advances in theranostic biomarkers for tumor immunotherapy. Curr Opin Chem Biol 2020;56:79-90. [PMID: 32217357 DOI: 10.1016/j.cbpa.2020.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
21 Park J, Park I, Kim I, Hur JY, Hwang I, Kim C, Kim H, Maeng CH, Park K, Lee M, Lee HJ, Jung JY, Keam B, Park SH, Lee JL. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. Current Problems in Cancer 2022. [DOI: 10.1016/j.currproblcancer.2022.100848] [Reference Citation Analysis]
22 Pradhan M, Chocry M, Gibbons DL, Sepesi B, Cascone T. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Transl Lung Cancer Res 2021;10:590-606. [PMID: 33569339 DOI: 10.21037/tlcr-20-573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
23 Zuazo M, Arasanz H, Bocanegra A, Fernandez G, Chocarro L, Vera R, Kochan G, Escors D. Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. Front Immunol 2020;11:586907. [PMID: 33329566 DOI: 10.3389/fimmu.2020.586907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
25 Zhang X, He Y, Jia K, Dziadziuszko R, Zhao S, Deng J, Wang H, Hirsch FR, Zhou C. Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer? Transl Lung Cancer Res 2019;8:559-74. [PMID: 31737493 DOI: 10.21037/tlcr.2019.09.20] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Shindo Y, Hazama S, Tsunedomi R, Suzuki N, Nagano H. Novel Biomarkers for Personalized Cancer Immunotherapy. Cancers (Basel) 2019;11:E1223. [PMID: 31443339 DOI: 10.3390/cancers11091223] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
27 Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer 2020;8:e000405. [PMID: 32350118 DOI: 10.1136/jitc-2019-000405] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
28 Takamori S, Ohba T, Shimokawa M, Matsubara T, Haratake N, Miura N, Toyozawa R, Yamaguchi M, Seto T, Takenoyama M. Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study). PLoS One 2021;16:e0258616. [PMID: 34679113 DOI: 10.1371/journal.pone.0258616] [Reference Citation Analysis]
29 Zhang Z, Yuan F, Chen R, Li Y, Ma J, Yan X, Wang L, Zhang F, Tao H, Guo D, Huang Z, Zhang S, Li X, Zhi X, Ge X, Hu Y, Wang J. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2020;11:1173. [PMID: 32587591 DOI: 10.3389/fimmu.2020.01173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Prelaj A, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastrandrea A, Ricci D, Catino A, Galetta D. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy. Clin Lung Cancer 2020;21:365-377.e5. [PMID: 32245624 DOI: 10.1016/j.cllc.2019.11.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
31 Shi WJ, Zhao W. Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective. Chin Med J (Engl) 2020;133:2466-75. [PMID: 32960841 DOI: 10.1097/CM9.0000000000001090] [Reference Citation Analysis]
32 Chen X, Meng F, Jiang R. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:746976. [PMID: 34900692 DOI: 10.3389/fonc.2021.746976] [Reference Citation Analysis]
33 Yamada T, Hirai S, Katayama Y, Yoshimura A, Shiotsu S, Watanabe S, Kikuchi T, Hirose K, Kubota Y, Chihara Y, Harada T, Tanimura K, Takeda T, Tamiya N, Kaneko Y, Uchino J, Takayama K. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. Cancer Med 2019;8:1521-9. [PMID: 30790471 DOI: 10.1002/cam4.2037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 32] [Article Influence: 7.7] [Reference Citation Analysis]
34 Tashima Y, Kuwata T, Yoneda K, Hirai A, Mori M, Kanayama M, Imanishi N, Kuroda K, Ichiki Y, Tanaka F. Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung. Sci Rep 2020;10:1243. [PMID: 31988315 DOI: 10.1038/s41598-019-57321-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
35 Shao Y, Wu B, Jia W, Zhang Z, Chen Q, Wang D. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. BMC Urol 2020;20:90. [PMID: 32631294 DOI: 10.1186/s12894-020-00665-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
36 Hurkmans DP, Verdegaal EME, Hogan SA, de Wijn R, Hovestad L, van den Heuvel DMA, Ruijtenbeek R, Welters MJP, van Brakel M, Basak EA, Pinedo HM, Lamers CHJ, van de Werken HJG, Groten JP, Debets R, Levesque MP, Dummer R, Kapiteijn E, Mathijssen RHJ, Aerts JGJV, van der Burg SH. Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. J Immunother Cancer 2020;8:e001607. [PMID: 33427690 DOI: 10.1136/jitc-2020-001607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ye X, Liu X, Yin N, Song W, Lu J, Yang Y, Chen X. Successful first-line treatment of simultaneous multiple primary malignancies of lung adenocarcinoma and renal clear cell carcinoma: A case report. Front Immunol 2022;13:956519. [DOI: 10.3389/fimmu.2022.956519] [Reference Citation Analysis]
38 Chen D, Mao Y, Xue Y, Sang Y, Liu D, Chen Y. Does the lymph node yield affect survival in patients with esophageal cancer receiving neoadjuvant therapy plus esophagectomy? A systematic review and updated meta-analysis. EClinicalMedicine 2020;25:100431. [PMID: 32775970 DOI: 10.1016/j.eclinm.2020.100431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Kang M, Ma X, Shi J, Chen G, Jin X, Wang J, Lin L, Wu Z, Chen K, Xu J, Huang P, Chen J. Distinct molecular phenotype and the potential prognostic value of immune prognostic index and tumor infiltrating lymphocytes in hepatoid adenocarcinoma of stomach. Transl Oncol 2022;19:101380. [PMID: 35276435 DOI: 10.1016/j.tranon.2022.101380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Sun Y, Zhai C, Chen X, Dong Z, Hou L, Zhou C, Jiang T. Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. Transl Lung Cancer Res 2019;8:748-59. [PMID: 32010554 DOI: 10.21037/tlcr.2019.10.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
41 Chen D, Mao Y, Ding Q, Wang W, Zhu F, Chen C, Chen Y. Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2020;58:888-98. [PMID: 32596715 DOI: 10.1093/ejcts/ezaa172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Hou Q, Xu H. Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Adv Exp Med Biol 2020;1248:143-66. [PMID: 32185710 DOI: 10.1007/978-981-15-3266-5_7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Ferrandino RM, Roof S, Garneau J, Haidar Y, Bates SE, Park YA, Bauml JM, Genden EM, Miles B, Sigel K. Neutrophil-to-lymphocyte ratio as a prognostic indicator for overall and cancer-specific survival in squamous cell carcinoma of the head and neck. Head Neck 2020;42:2830-40. [PMID: 32592262 DOI: 10.1002/hed.26329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133-150. [PMID: 30755690 DOI: 10.1038/s41568-019-0116-x] [Cited by in Crossref: 726] [Cited by in F6Publishing: 703] [Article Influence: 242.0] [Reference Citation Analysis]
45 Yang Y, Liu X, Song W, Lu J, Yin N, Ye X, Chen X. Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit. Front Immunol 2022;13:907705. [DOI: 10.3389/fimmu.2022.907705] [Reference Citation Analysis]
46 Ni L, Huang J, Ding J, Kou J, Shao T, Li J, Gao L, Zheng W, Wu Z. Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Nutr 2022;9:823087. [DOI: 10.3389/fnut.2022.823087] [Reference Citation Analysis]
47 Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. Cancers (Basel) 2019;11:E1954. [PMID: 31817541 DOI: 10.3390/cancers11121954] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
48 Avdonkina NA, Danilova AB, Nekhaeva TL, Prosekina EA, Emelyanova NV, Novik AV, Girdyuk DV, Gafton GI, Baldueva IA. Clinical and immunological characteristics of sarcomas patients with clonogenic tumors. Immunobiology 2021;226:152094. [PMID: 34052775 DOI: 10.1016/j.imbio.2021.152094] [Reference Citation Analysis]
49 Malkova AM, Sharoyko VV, Zhukova NV, Gubal AR, Orlova RV. Laboratory biomarkers of an effective antitumor immune response. Clinical significance. Cancer Treat Res Commun 2021;29:100489. [PMID: 34837797 DOI: 10.1016/j.ctarc.2021.100489] [Reference Citation Analysis]
50 Chen D, Mao Y, Wen J, She Y, Zhu E, Zhu F, Zhang Y, Fan M, Chen C, Chen Y. Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Ann Thorac Surg 2019;108:945-54. [PMID: 30914285 DOI: 10.1016/j.athoracsur.2019.02.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]